Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

UK health regulator approves GSK’s vaccine for common respiratory virus RSV

by Staff GBAF Publications Ltd
0 comment

UK health regulator approves GSK’s vaccine for common respiratory virus RSV

(Reuters) -Britain’s health regulator approved GSK’s vaccine for the respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually, the drugmaker said on Monday.

The Medicines and Healthcare products Regulatory Agency (MHRA) authorised GSK’s shot, called Arexvy, for active immunisation to prevent lower respiratory tract disease caused by RSV in adults 60 years and older, the company said.

RSV typically causes cold-like symptoms but is a leading cause of pneumonia in toddlers and the elderly.

The complex molecular structure of the virus and safety concerns with previous vaccine attempts had stymied efforts to successfully develop a shot since the virus was first discovered in 1956.

Arexvy has recently got the green light from the United States and European regulators.

(Reporting by Eva Mathews in Bengaluru; Editing by Savio D’Souza and Dhanya Ann Thoppil)